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ABSTRACT: The knowledge on human serum albumin (HSA)
binding is of utmost importance as it affects pharmacokinetic
behavior and bioavailability of drugs. In this article, we report a
novel method to screen for ionizable molecules with high HSA
binding affinity based on pKa shifts using UV-pH titration. We
investigated the HSA binding of 27 drugs and compared the results
to experimental data from conventional methods. In most cases,
significant shifts (ΔpKa > 0.1) were observed for drugs with high
HSA binding, while no change could be detected for low-affinity
binders. We showed the pivotal role of ionization centers in the
formation of strong interactions between drug and HSA using
molecular docking studies. We also verified our findings by testing
five modified analogues designed by structural considerations.
Significant decreases in their HSA binding proved that the UV-pH titration method combined with an in silico support can be used
as a medicinal chemistry tool to assist rational molecular design.
■ INTRODUCTION
Active pharmaceutical ingredients (API) entering the system-
atic circulation may interact with various components of the
blood, which directly affects their pharmacokinetic and
pharmacodynamic behaviors.1−5 Blood plasma consists of
approximately 7−9% of plasma proteins (albumins, glyco-
proteins, and fibrinogen), which contribute a major part to
API-specific interactions. Among them, human serum albumin
(HSA) is the most abundant (about 54−60% of blood
proteins),6−8 which is present in the blood at particularly high
concentrations (35−50 g/L).8−11 It plays an important role in
maintaining the osmotic pressure of the blood, serves as a
transport protein for endogenous substances (e.g., fatty acids
and steroid hormones), and it is also the main contributor to
the binding of drug molecules.5,7,8,10 The protein’s heart-
shaped structure is composed of three main domains (I−III),
each containing two subdomains (A and B).8−10 Besides the
several recently identified low- to high-affinity binding sites of
HSA,12,13 the two specific drug binding sites (site I: warfarin
site on the IIA subdomain and site II: indole-benzodiazepine
site on the IIIA subdomain) are considered to be the most
significant, regarding plasma protein binding.8,11,14−18 Drug
molecules usually form reversible complexes with HSA by
electrostatic and hydrophobic interactions. These HSA−API
complexes cannot cross biological membranes; therefore, they
become therapeutically inactive.5,19 Moreover, strong binding
may also have a significant effect on the pharmacokinetic (PK)
behavior of APIs (e.g., altered clearance,20−22 distribution,19−21
drug−drug interactions,19,23 and toxicity24). The HSA binding
affinity shows wide diversity for drug-like compounds; thus, it
is essential to predict the unbound fraction of APIs from the
early stages of drug discovery for the estimation of PK
behavior.
For the measurement of HSA-binding properties of APIs,
several in vitro methods exist,18,19,25−27 including equilibrium
dialysis (ED),28,29 ultrafiltration (UF),30 ultracentrifugation,31
chromatographic methods,32−35 NMR spectroscopy,36,37 X-ray
crystallography,38 capillary electrophoresis (CE),39 etc. These
methods differ in throughput and time of the measurement
have different sample requirements and limitations, and each
has its advantages and disadvantages (Table 1.). Also, most of
the methods are able to provide information solely about the
APIs’ affinity to HSA, while structural information regarding
the interactions between HSA and APIs can be acquired by
only a few timely and expensive techniques (e.g., NMR and X-
ray diffraction). Besides the experimental methods, in silico
models can be used to predict HSA binding, while molecular
modeling studies can also be used to explore possible binding
modes between HSA and APIs, providing additional structural
information on complex formation.40 To give a thoroughly
detailed description of the complexes, data from orthogonal
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methods are needed to be evaluated and compared
simultaneously.
This study aims to present a UV-pH titration method as a
novel approach to screen for high-affinity HSA-binding
ionizable APIs. By means of the method, additional structural
information might also be gathered, and the role of ionization
centers in the interaction between HSA and APIs can be
further elucidated to help medicinal chemists in their efforts
toward rational molecular design.
Theoretical Basis of UV-pH Titration. Spectrophotom-
etry can be applied for the measurement of proton dissociation
constants (pKa) provided that the compound has a
chromophore in proximity to the ionization center and the
absorbance changes sufficiently as a function of pH. In aqueous
solutions, the dissociation equilibrium of a monoprotic acid
and the acid dissociation constant (Ka) can be written as
HA A H+− +F (1)
K
A H
HAa
= [ ][ ]
[ ]
− +
(2)
where HA and A− are the neutral and dissociated forms of the
acid, respectively. After rearrangement of eq 2 and taking
logarithms, we acquire the Henderson−Hasselbalch equation
KpH p log
A
HAa
= + [ ]
[ ]
−i
k
jjjj
y
{
zzzz (3)
If there is a pH-dependent change in absorbance, the ratio of
HA and A− can be determined spectrophotometrically.43 At a
pH where the molecule exists entirely in its neutral form, its
absorbance at a given wavelength is given by
Table 1. Summary of Commonly Used Experimental Methods for the Investigation of HSA−API binding18,19,25−27a
method type
measurement time/
throughput pros cons
Quantitative Binding Data
chromatography and capillary
electrophoresis32−35,39
0.5 h/API HT accurate results nonbiological systems
no NSB, volume shift, or membrane
leakage
calibration of immobilized HSA column is needed before
measurements
high solvent consumption and waste generation
poor sensitivity for low-binding APIs
expensive chiral columns
membrane separation methods reliable results Gibbs−Donnan effects
NSB on filter membranes and plastic devices
possible leakage of membrane
subsequent HPLC measurements
equilibrium dialysis (ED) 3 to 24 h long time to reach equilibrium
volume shifts during incubation
dilution effects
rapid equilibrium dialysis
(RED)28,29
2−7 h HT reaching equilibrium faster than ED possible leakage of membrane
small volumes can be measured plate accessories can be expensive (although inexpensive
devices have been developed41)NSB and volume shifts minimalized
ultrafiltration (UF)30 1−2 h HT fast separation of free and protein-
bound API
NSB on filter membrane and device
small volumes can be measured possibility of molecular sieving
good approximation of physiological
conditions
pH and temperature controls are more difficult
ultracentrifugation31,42 10−24 h MT moderate NSB and Donnan effect time-consuming, careful pH and temperature controls are
needed
errors due to the Johnston−Ogston effect
sedimentation of unbound API may occur
sample harvesting is difficult due to the floating lipid layer
expensive instrumentation
Structural Information
X-ray crystallography38 days to months, LT yields the most accurate structural
information
impurities of the protein may hinder crystallization
binding sites can be identified difficulty to determine correct crystallization conditions
solubility problems of API may arise
precipitation or growth of tiny crystals may occur
Binding and Structural Information
NMR36,37 hours to days, LT noninvasive technique APIs with low aqueous solubility cannot be measured in
physiological buffersno separation step or subsequent
measurement needed
UV-pH titration 0.5 hb to 1−2 h MT fast method for screening only ionizable molecules can be measured
may provide additional structural
information of binding
absorbance of HSA may interfere
APIs with low aqueous solubility can
be measured
aAPI, active pharmaceutical ingredient; NSB, nonspecific binding; HT, high throughput; MT, medium throughput; and LT, low throughput. bIf
aqueous pKa values without HSA have already been determined.
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A l HAHA HAε= × × [ ] (4)
where εHA and [HA] are the molar absorption coefficient and
concentration of HA, respectively, and l is the optical path
length. At a pH where the molecule exists entirely in its
dissociated form, the absorbance of A− is given by
A l AA Aε= × × [ ]−− − (5)
where εA− and [A
−] are the molar absorption coefficient and
concentration of A−, respectively. At an intermediate pH where
both species are present, the absorbance is given as
A l lHA Ai HA Aε ε= × × [ ] + × × [ ]−− (6)
Combining eqs 4−6, the ratio of HA and A− can be written
as
A A
A A
A
HA
i HA
A i
[ ]
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−
−
− (7)
Combining eqs 3 and 7 provides a modified Henderson−
Hasselbalch equation, which can be used to calculate pKa
values based on absorbance changes43
K
A A
A
pH p log
Aa
i HA
A i
= + −
−−
i
k
jjjjj
y
{
zzzzz (8)
If the conditions for UV-pH measurements coincide, then
this method is the fastest way for the determination of pKa
values (approximately 20−25 min/3 parallel measurements).
Furthermore, the sample requirement of built-in UV-pH
methods of the SiriusT3 instrument is also minuscule, and
only 5 μL of a 10 mM stock solution (DMSO, MeCN, etc.) of
the API is needed in a titration volume of 1 mL. Also,
measurements in the presence of co-solvents, macromolecules,
or additives may be possible, making it an ideal choice for
complexation studies as well.
Upon complexation with macromolecules (e.g., cyclo-
dextrins, crown ethers, proteins, etc.), the dissociation
equilibrium and the acid dissociation constant can be written
as
HA G A G H· · +− +F (9)
K
A G H
HA Ga
* = [ · ][ ]
[ · ]
− +
(10)
where G is the guest molecule, and Ka* is the apparent proton
dissociation constant of the complexed API. Due to different
absorption properties of the complexed species, a significant
spectral change may occur.44 If absorption of the guest
molecule is negligible and addition of absorbances is assumed,
then the absorbances of the molecular species can be given as
A l lHA HA GHA HA HAGε ε= × × [ ] + × × [ · ] (11)
A l lA A GA A AGε ε= × × [ ] + × × [ · ]− −− − − (12)
A l l
l l
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A AG
ε ε
ε ε
= × × [ ] + × × [ · ]
+ × × [ ] + × × [ · ]− −− − (13)
Substituting eqs 11−13 into eq 8, the apparent pKa values
(pKa,app) can be calculated with shifts from pKa values that are
proportional to the ratio of bound and unbound fractions.
■ RESULTS AND DISCUSSION
HSA-Binding Measurements by UV-pH Titration. We
investigated the possibility of measuring HSA binding of APIs
based on changes of proton dissociation constants of their free
and complexed molecular forms using UV-pH titration. First,
we collected UV−vis absorbance data of HSA during the UV-
pH titration assay to determine if the presence of HSA would
interfere with the signal of APIs. As can be seen in Figure 1
(left), HSA has two pKa values (pKa1 = 3.87 and pKa2 = 11.56),
which are measurable by UV-pH titration. If we add HSA to
the blank UV-pH titration assay (Figure 1, right), it annuls the
spectral changes belonging to the first pKa value; however, the
Figure 1. pH-dependent UV−vis absorbance changes and detectable pKa values of HSA in the absence (left) and in the presence (right) of blank
correction.
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second pKa value remains detectable even after blank
correction. Therefore, even though the intensity of the signals
of the second pKa value is decreased, we must consider the
presence of overlapping absorption bands during titrations of
APIs.
Next, we investigated HSA binding of APIs by measuring
their pKa values in aqueous medium in the absence of HSA and
in the presence of HSA (pKa,HSA). Figure 2 shows some
examples of the acquired spectra and experimental pKa values
in the presence and absence of HSA. We observed significant
pKa shifts (ΔpKa) for several APIs, while others showed no
change of pKa values upon addition of HSA (Table 2 and
Table S1, Supporting Information). In the case of molecules
with multiple protonation centers, their pKa values changed to
varying extent; we proposed that this might indicate which part
of the molecule contributes more to the binding to HSA. This
was later confirmed by molecular docking studies (see the next
section for further details). In some cases, absorption bands of
HSA suppressed the absorbance of the API; therefore, pKa,HSA
could not be determined. This usually occurred in the case of
APIs with only minuscule pH-dependent absorbance changes
in their spectrum in aqueous medium (e.g., diltiazem,
imipramine, indomethacin, and propranolol) or in the case
of pKa values higher than ∼10 (e.g., furosemide pKa2 and
amodiaquine pKa3) where the signals of pKa2 of HSA
interfered. We could avoid this latter problem if the API had
significant absorption at wavelengths higher than 320 nm (e.g.,
chloroquine pKa2, nitrazepam pKa2, and oxazepam pKa2),
Figure 2. Absorbance spectra and detectable pKa values of diclofenac (DIC), phenylbutazone (PHB), piroxicam (PIR), and procaine (PRC) in the
presence and absence of HSA.
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where no interference with HSA absorption bands was
observed and thus evaluation of data was possible.
Comparison of the Results with Reference Values. To
compare our results with data from orthogonal methods, we
also measured HSA binding of the APIs using chromatographic
measurements on an immobilized HSA column using rapid
equilibrium dialysis (RED) and carried out molecular docking
of some APIs (Figure 3) into the crystal structure of HSA. We
found that in the case of compounds with high HSA binding,
significant shifts (ΔpKa > 0.1) could be observed for at least
one pKa value, while no change of pKa values can be expected
for APIs with lower HSA binding (HSA% less than ∼40%).
However, in some cases (e.g., diazepam (DZP)), the results of
UV-pH titration (ΔpKa = 0.09) contradicted the data from
orthogonal methods (HSA binding, >90%).
Among the studied drugs, pKa shifts (from free to HSA-
bound form) around or greater than 0.4 units were observed
for chloroquine (CHQ; ΔpKa2, 0.75), diclofenac (DIC; ΔpKa,
0.47), diflunisal (DIF; ΔpKa2, 0.38), meloxicam (MEL; ΔpKa2,
0.55), nitrazepam (NZP; ΔpKa2, 0.98), phenylbutazone (PHB;
ΔpKa, 0.53), piroxicam (PIR; ΔpKa2, 0.55), and tenoxicam
(TEN; ΔpKa2, 0.72). In each case, the pKa shifted toward a
more acidic value, favoring the deprotonated form of the APIs
when bound to HSA. To understand the structural basis of
these changes, the available X-ray structures of human serum
albumin (HSA) were scrutinized. From the mentioned APIs,
co-crystallized structures with HSA exist for DIC (PDB:
4Z6950), DIF (PDB: 2BXE51), and PHB (PDB: 2BXC51).
Notably, DIC and PHB bind to drug site I (“warfarin site”),
while DIF binds to drug site II (indole-benzodiazepine site).
Although the exact hydrogen positions are not available at the
resolution of these structures, the immediate vicinity of the
ligand protonatable groups to positively charged amino acids
(such as the K195-K199-R218-R222 cluster in drug site I or
R410-K414 in drug site II) strongly implies the preference
toward the deprotonated forms of the APIs. The experimental
binding modes were evaluated with the extra precision (XP)
mode of Glide for both the protonated and deprotonated
forms (refinement only): per-residue Coulomb interaction
Table 2. Literature Data and Experimental Values of HSA Binding by Chromatographic, Rapid Equilibrium Dialysis (RED),
and UV-pH Titration Measurements
literature data experimental data
UV-pH titration
API name PPB%4,45−47 HSA% (HPLC)48,49 HSA% (HPLC) HSA% (RED) ΔpKa1 ΔpKa2
amodiaquine 78.8 0.12 ± 0.04 0.64 ± 0.03
cefuroxime 33 ± 3; 31.5 40.1 n.d.a n.d.a
chloroquine (S): 66.6 ± 3.3 50.5b 0.21 ± 0.03 0.75 ± 0.05
(R): 42.7 ± 2.1
diazepam 98.7 ± 0.2; 99 93.2 89.2 n.d.c 0.09 ± 0.03
diclofenac >99.5; 99.5 99.0 100.0 95.8 ± 0.2 0.47 ± 0.01
diclofenac ethyl ester 98.1 n.d.c
diflunisal 99 98.7 100.0 ∼100 0.38 ± 0.04 n.d.a
diflunisal ethyl ester 97.5 n.d.c
diltiazem 78 53.9 56.6 n.d.a
famotidine 20 14.5 25.1 4.4 ± 2.6 0.02 ± 0.03
furosemide 98.4 63.8 99.4 0.10 ± 0.01 n.d.a
imipramine 90.1 ± 1.4; 92.6 83.1 84.9 n.d.a
indomethacin 90; 92−99 99.5 100.0 95.8 ± 0.2 n.d.a
isoniazid ∼0 6.8 10.9 0.05 ± 0.03 n.d.a
isoxicam 97.3 80.4 ± 0.8 0.22 ± 0.05
lornoxicam 100.0 98.0 ± 0.2 0.87 ± 0.23d 1.00 ± 0.07
meloxicam 99 99.9 96.7 ± 0.1 0.16 ± 0.23d 0.55 ± 0.05
O-methyl meloxicam 84.2 65.9 ± 1.8
metronidazole 10; 11 ± 1 5.4 11.9 0.00 ± 0.01
nitrazepam 82.3 76.7 n.d.c 0.05 ± 0.03 0.98 ± 0.06
oxazepam 98.4 94.2 79.9, 89.5 n.d.c 0.06 ± 0.03 0.27 ± 0.03
phenylbutazone 97.8; 98−99 98.4 99.9 96.3 ± 0.5 0.53 ± 0.05
C-methyl phenylbutazone 85.0 64.1 ± 1.8
O-methyl phenylbutazone 92.9 92.9 ± 1.9
physostigmine 20.0 9.7 ± 6.6 0.05 ± 0.03
piroxicam 99; 99 96.8 100.0 93.3 ± 0.3 0.00 ± 0.04 0.55 ± 0.09
procaine 6 36.0 21.0 6.4 ± 0.4 0.02 ± 0.06 0.00 ± 0.06
propranolol 87 ± 6; 87 62.0 62.5 n.d.a
sulindac 94; 93.5 92.0 98.2 64.9 ± 6.9 0.16 ± 0.06
tenoxicam 100.0 96.8 ± 0.0 0.13 ± 0.11d 0.72 ± 0.09
trimethoprim 37.5; 41.5 37.6 37.3 3.1 ± 4.6 0.01 ± 0.02
warfarin 99 ± 1; 99 97.9 99.9, 100.0 91.5 ± 0.7 0.41 ± 0.05
aExperimental data has been measured using a racemic compound. bHSA binding could not be determined due to chemical decomposition during
incubation. cHSA suppressed the absorbance of the API, and pKa,HSA could not be determined.
dHigh standard deviations originate from
extrapolated pKa values, out of the measurement range of UV-pH titration.
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scores between the ligands and the mentioned charged
residues confirm this implication (Figure 4).
For the remaining five APIs, Glide XP was used to predict
their binding modes in the two drug sites of HSA by docking
to the X-ray structures 2BXC and 2BXE. The poses were
inspected with regard to the vicinity of the protonatable groups
(specifically, the ones with the significant pKa shifts) to
potential ionic interaction partners. For four APIs, such a
binding pose was identified in drug site I (as the most favorable
binding pose in each case), and the differences of the Coulomb
interaction scores confirm the preference toward the
deprotonated forms (Figure 5). For CHQ (the only API
with a formal positive charge in its protonated form), no such
binding mode was identified in either drug site. We propose
that in the case of CHQ, the deprotonated form is favored
because ligand entry to both drug sites is hindered for the
protonated form due to the repulsive interactions with the
positively charged residue clusters at the entry points of the
sites (K195-K199-R218-R222 in drug site I and R410-K414 in
drug site II, see also Figure 4).51
Due to the contradictory UV-pH titration results of DZP, to
find possible explanations, we compared X-Ray structures
(where available) and predicted binding modes of DZP and its
structural analogue NZP (Figure 6). In the X-ray structure
2BXD, DZP occupies drug site II (A), with its only
protonatable nitrogen being too far from the R485 residue to
make direct contact. Although its predicted binding mode in
site I (B) would justify a pKa shift (the same nitrogen being
only 3.0 Å away from R257), binding to this site is not
observed in the crystal structure, suggesting that site II is
clearly preferred. Thus, the protonatable nitrogen will not be
able to directly interact with HSA, which can explain the
smaller than expected pKa shift. On the contrary, in the
predicted binding mode of NZP to drug site II (C), the
deprotonatable amide nitrogen is too far from R410 to make
direct contact, but the predicted binding mode in drug site I
(D) nicely supports the observed pKa shift of 0.56 units (by
Figure 3. Structure of APIs investigated by molecular modeling studies. CHQ, chloroquine; DIC, diclofenac; DIF, diflunisal; DZP, diazepam; MEL,
meloxicam; NZP, nitrazepam; PHB, phenylbutazone; PIR, piroxicam; and TEN, tenoxicam.
Figure 4. Refined experimental binding modes for the deprotonated (green) and protonated (magenta) forms of (A) diclofenac, (B)
phenylbutazone, and (C) diflunisal (C). Coulomb interaction scores with the most important interacting residues are shown in matching colors,
the smaller the better. (While in phenylbutazone, formally, the ring CH gets deprotonated, and practically, the negative charge is located on one of
the oxo groups due to tautomerization).
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://dx.doi.org/10.1021/acs.jmedchem.0c00046
J. Med. Chem. XXXX, XXX, XXX−XXX
F
placing the amide nitrogen 3.4 Å away from R257), suggesting
the preference of NZP toward drug site I.
Use of UV-pH Titration To Assist Medicinal Chem-
istry. As the previous examples show, UV-pH titration
combined with molecular modeling can be used to identify
the role of ionization centers in the formation of strong API−
HSA interactions. The information gathered this way might be
used to help chemists to design molecules with decreased HSA
binding, which might improve the API pharmacokinetics and
increase their bioavailability. For validation purposes, some of
the APIs with considerable pKa shifts (DIC, DIF, MEL, and
PHB) were modified by ester formation or alkylation to
neutralize their protonatable groups; these analogues were
evaluated with the same protocols as described above.
The chromatographic measurements showed a significant
decrease in retention time for each modified API, indicating a
lower HSA binding affinity (Table 2 and Figure 7). We
observed moderate decreases in binding for DIC ethyl ester
Figure 5. Refined predicted binding modes for the deprotonated (green) and protonated (magenta) forms of (A) meloxicam, (B) nitrazepam, (C)
piroxicam, and (D) tenoxicam. Coulomb interaction scores with the most important interacting residues are shown in matching colors, the smaller
the better.
Figure 6. Comparison of crystallographic and predicted binding modes of (A, B) diazepam and (C, D) nitrazepam, with distances of the relevant
protonatable groups to the closest charged residues.
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(100% → 98.1%) and DIF ethyl ester (100% → 97.5%) and
extensive decreases in the case of O-methyl MEL (99.9% →
84.2%), O-methyl PHB (99.9%→ 92.9%), and C-methyl PHB
(99.9%→ 85.0%). RED measurements also showed significant
decreases in the binding of modified MEL (99.9% → 65.9%)
and PHB (99.9% → 92.9% (O-methyl PHB) and 99.9% →
85.0% (C-methyl PHB)), while HSA binding could not be
determined this way for the esters of DIC and DIF due to their
instability under the measurement conditions of RED (Table
2).
To further support the experimental results, molecular
docking studies have also been carried out to compare binding
modes of the analogues. For the ethyl ester of DIF, the O- and
C-methylated PHB, and the ethyl ester of DIC, the top binding
modes predicted by Glide XP docking were closely similar to
their respective unmodified counterparts. Nonetheless, the
Coulomb interaction scores against the charged residues were
small, as expected (Figure 8). For O-methyl MEL, unrestrained
Glide XP docking could not identify a binding mode similar to
that of the unmodified API. When restricted to the reference
binding mode of meloxicam, the modified analogue exhibits
repulsive Coulomb interaction scores, while in its unrestricted
binding mode, the interaction scores confer slightly and in one
case (K199), moderately attractive contributions, similar to the
other analogues.
As the results of experimental measurements and molecular
modeling show, we succeeded in using UV-pH titration as a
screening tool for identifying structural moieties that make
major contribution in formation of complexes with strong
binding. By the modification of the APIs, the ionization centers
responsible for strong interactions with HSA could be
neutralized, resulting in a lower HSA binding. Since even a
few percent decreases have a considerable effect on the
distribution of APIs,5 the observed decreases in HSA binding
(from 2−3 to 10−35%) support the technique’s applicability
to help the design of novel molecules with favorable
pharmacokinetic behavior.
■ CONCLUSIONS
In this study, we demonstrated the applicability of UV-pH
titration as an orthogonal method for the identification of APIs
with high-affinity binding. This fast and cost-effective method
can be used as a screening assay in the case of molecules
containing ionization centers, providing binding data faster
than conventional methods. We showed that the observed pKa
shifts (ΔpKa) are proportional to HSA binding of APIs. In the
case of multiprotic molecules, by means of molecular docking,
we demonstrated that the pKa shifts of different sizes provide
structural information on the binding mode of the API. To
elucidate the significance of ionization centers of molecules, we
also investigated modified analogues with neutralized proto-
nation centers. The results clearly showed that decreased
protein binding can be achieved by this approach, resulting in
molecules with improved pharmacokinetics. Therefore, the
UV-pH titration method combined with an in silico support
might be used as a novel medicinal chemistry tool to assist
researchers in the rational drug design to decrease the high
attrition rate in later stages of drug discovery. In the future,
besides screening for APIs with high-affinity binding, this
method might also be used for comparison of binding of a
specific API with different kinds of modified HSA derivatives
or in the case of different formulations of HSA.
■ EXPERIMENTAL SECTION
Materials. Analytical grade solvents such as acetonitrile (MeCN),
dimethyl sulfoxide (DMSO), ethanol (absolute), formic acid,
trifluoroacetic acid (TFA), and potassium hydroxide (KOH) were
purchased from Merck KGaA (Darmstadt, Germany). Analytical
grade 2-propanol (IPA), 0.5 M hydrochloric acid, and 0.5 M
potassium hydroxide were purchased from Honeywell International
Figure 7. Chromatograms of diclofenac (DIC), diflunisal (DIF), meloxicam (MEL), phenylbutazone (PHB), and their modified forms with
neutralized ionization centers. (Due to low absorbance of O-methyl MEL, its extracted ion chromatogram (EIC) (m/z = 366.0) was also used for
peak identification).
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Inc. (New Jersey, USA). Albumin from human serum (lyophilized
powder, ≥97% (agarose gel electrophoresis) cat. no.: A9511),
ammonium acetate (NH4OAc), dichloromethane (DCM), ethyl
acetate (EtOAc), methyl iodide (MeI), phosphate-buffered saline
(PBS) powder, potassium chloride, and the reference materials
(acetaminophen, amodiaquine dihydrochloride dihydrate, amoxicillin,
ampicillin, antipyrine, aspirin, atenolol, captopril, carbamazepine,
cefotaxime sodium, cefuroxime sodium, cephalexin, chloroquine
diphosphate, chlorothiazide, chlorpromazine hydrochloride, cimeti-
dine hydrochloride, clonidine hydrochloride, diazepam, diclofenac
sodium, diflunisal, diltiazem hydrochloride, diphenhydramine hydro-
chloride, famotidine, furosemide, imipramine hydrochloride, indome-
thacin, isoniazid, isoxicam, ketoconazole, meloxicam, metronidazole,
naproxen, nifedipine, nitrazepam, oxazepam, phenylbutazone, pheny-
toin, physostigmine, piroxicam, procaine hydrochloride, propranolol
hydrochloride, ranitidine hydrochloride, rifampin, sulfamerazine,
sulfamethoxazole, sulindac, terbutaline hemisulfate, trimethoprim,
and warfarin) were purchased from Sigma-Aldrich Co., Ltd.
(Budapest, Hungary). Diclofenac ethyl ester, ketorolac tromethamine,
and O-methyl meloxicam were purchased from Toronto Research
Chemicals Inc. (North York, Toronto, Canada). Lornoxicam and
tenoxicam were purchased from Carbosynth Ltd. (Compton,
Berkshire, United Kingdom). O-methyl phenylbutazone was pur-
chased from Ambinter c/o Greenpharma S.A.S. (Orleáns, France).
Diflunisal ethyl ester and C-methyl phenylbutazone were synthesized
at Gedeon Richter Plc. Compounds possessed a purity of >95% by
means of HPLC. (Diflunisal ethyl ester: SHIMADZU prominence
modular HPLC system equipped with a photodiode array detector
(PDA) and a mass spectrometer equipped with an electrospray
ionization source (ESI); column: CORTECS C18+, 90 Å, 2.7 μm
(3.0 × 50 mm); retention time = 3.89 min; peak area, 98.76%; eluent
A, 0.1% (v/v) formic acid in water; eluent B, MeCN/water 95:5 (v/v)
with 0.1% (v/v) formic acid; gradient: 0−4.5 min/2−100% B and
4.5−5.6 min/100% B; flow rate of 1.25 mL/min; detection at 220 ± 4
nm; column temperature: 40 °C. C-methyl phenylbutazone: Agilent
1200 liquid chromatography system equipped with a diode array
detector and coupled with an Agilent 6410 triple quadrupole mass
spectrometer (QQQ-MS) equipped with an ESI source; column:
Kinetex EVO C18, 100 Å, 2.6 μm (3.0 × 100 mm); retention time =
8.60 min; peak area, 99.77%; eluent A, 0.1% (v/v) TFA in water;
eluent B, MeCN/water 95:5 (v/v) with 0.1% (v/v) TFA; gradient:
0−15 min/0−100% B and 15−18 min/100% B; flow rate of 1 mL/
min; detection at 220 ± 4 nm; column temperature: 45 °C.) For
detailed information on their syntheses and confirmation of structures
(NMR and HRMS), see the Supporting Information (Sections 4−6).
Neutral linear buffer (NLB) was purchased from Pion Inc. (U.K.) Ltd.
(Forrest Row, United Kingdom). In all experiments, distilled water
Figure 8. Predicted binding modes for (A) diflunisal ethyl ester, (B) C-methyl phenylbutazone, (C) O-methyl phenylbutazone, (D) O-methyl
meloxicam, and (E) diclofenac ethyl ester. For methoxy-meloxicam, the binding mode with the core position restricted to the binding mode of
meloxicam is shown in orange. Coulomb interaction scores with the most important charged residues are shown in matching colors (the smaller the
better): these are mostly slightly attractive (and in some cases, slightly repulsive), similar to the protonated forms of the original APIs. By
comparison, the deprotonated forms of the APIs exhibit large negative (strongly attractive) Coulomb contributions (see Figures 4 and 5).
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was purified by the Millipore Milli-Q 140 gradient water purification
system.
UV-pH Titration. The UV-pH titrations were performed using a
fully automated SiriusT3 instrument (Pion Inc., Forest Row, U.K.).
Spectrophotometric determination of pKa values was performed using
the built-in fast UV pKa method, the absorbance changes during the
titrations were monitored by the dip-probe absorption spectroscopy
(D-PAS) method,52,53 and evaluation and calculation of pKa values
were performed by the SiriusT3Refine software (version 1.1.3.0., Pion
Inc., Forest Row, U.K.). For the determination of pKa values in
aqueous media, 5 μL of 10 mM DMSO solution of the samples was
titrated from pH 2.0 to pH 12.0 in 1.5 mL ionic strength adjusted
water (ISA-water: 0.15 M KCl; the initial sample concentration is
approximately 33.3 μM). In the case of determination of pKa values in
the presence of HSA (pKa,HSA), a modified fast UV assay was used:
ISA-water solutions containing HSA (33.3 μM, with a 1:1 nominal
molar ratio of HSA and APIs) were added manually in advance to the
titration vials. All measurements were performed under a nitrogen
atmosphere at T = 25.0 ± 0.1 °C. The pH region 2.0−10.0 and the
spectral region of 250−450 nm were used in the analysis, and the
results were calculated from a minimum of three replicates in each
case.
Molecular Docking. Ligand and protein structures were prepared
with the standard tools of the Schrödinger software package,54−56
based on the OPLS3 force field.57 For ligand docking and the
generation of per-residue interaction scores, the extra precision mode
(XP) of Glide was used.58,59 The publicly available PDB structures
2BXC, 2BXE,51 and 4Z6950 were used for evaluating the experimental
binding modes of PHB, DIF, and DIC, respectively. For the additional
five APIs, the structures 2BXC and 2BXE were used to generate
predicted binding modes with Glide XP, after validating them by
redocking their cognate ligands into the respective binding pockets.
(RMSD values between experimental and predicted poses were 1.40
and 1.01 Å for 2BXC and 2BXE, respectively, and 5.60 Å for 4Z69;
therefore, this structure was omitted from further use.) The best
identified binding pose was refined for both the protonated and
deprotonated forms of the APIs.
For detailed description of HSA-binding measurement by RED and
biomimetic chromatography, see the Supporting Information.
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Dávid Bajusz − Medicinal Chemistry Research Group, Research
Centre for Natural Sciences, 1117 Budapest, Hungary;
orcid.org/0000-0003-4277-9481
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and Prof. Csaba Szańtay Jr. for NMR measurements, and to
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